life sciences
The $9.4 Billion Bet on Code: Why Thermo Fisher’s Mega-Deal for a Software Company Is Reshaping Medicine
Thermo Fisher’s $9.4B acquisition of Clario isn’t just a deal; it’s a bet on the future of medicine, powered by software, AI, and cloud technology.
UK at a Crossroads: Fix Systemic R&D or Forfeit Economic Superpower Status?
A stark report warns the UK’s systemic R&D weakness threatens its economy. Without decisive action, major projects and investments are at risk.
Thermo Fisher’s $10 Billion Bet: Unpacking the Mega-Deal for Clario and the Future of Drug Development
Thermo Fisher’s potential $10B acquisition of Clario signals a major shift in the drug development landscape, blending healthcare, data, and finance.